On 4 February 2026, Farmak, a pharmaceutical company, hosted a delegation of the International Monetary Fund (IMF) led by Priscilla Toffano, IMF Resident Representative in Ukraine.
The visit began with a guided tour of Farmak’s manufacturing facilities in Kyiv. The delegation visited the company’s aseptic production unit, where Farmak manufactures infusion, injectable, and inhalation medicines for both the Ukrainian market and export. These include anesthetics, contrast agents for MRI diagnostics, antibiotics for the treatment of severe bacterial infections, glucocorticosteroids used in allergic reactions, inflammatory conditions, cerebral edema, and shock states, as well as antipsychotic and analgesic medicines, treatments for respiratory diseases, and other pharmaceutical products.
During the presentation session, Farmak’s management briefed the IMF representatives on the company’s operations, its role in the Ukrainian pharmaceutical market, export activities, and investments in production and development.
Special attention was given to the challenges of doing business amid the full-scale war, the impact of macroeconomic factors on the industry, the new regulatory framework for the pharmaceutical market, as well as Ukraine’s European integration processes and alignment with EU standards.
The meeting concluded with an informal discussion and an exchange of views on future challenges and opportunities for Ukrainian businesses under the current conditions.
